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Abstract
Objective
We assessed the association between gender and mortality on antiretroviral therapy (ART)
using identical models with and without sex-specific categories for weight and hemoglobin.
Design
Cohort study of adult patients on ART.
Setting
GHESKIO Clinic in Port-au-Prince, Haiti.
Participants
4,717 ART-naïve adult patients consecutively enrolled on ART at GHESKIO from 2003 to
2008.
Main OutcomeMeasure
Mortality on ART; multivariable analyses were conducted with and without sex-specific cat-
egories for weight and hemoglobin.
Results
In Haiti, male gender was associated with mortality (OR 1.61; 95% CI: 1.30–2.00) in multi-
variable analyses with hemoglobin and weight included as control variables, but not when
sex-specific interactions with hemoglobin and weight were used.
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Conclusions
If sex-specific categories are omitted, multivariable analyses indicate a higher risk of mortal-
ity for males vs. females of the same weight and hemoglobin. However, because males
have higher normal values for weight and hemoglobin, the males in this comparison would
generally have poorer health status than the females. This may explain why gender differ-
ences in mortality are sometimes observed after controlling for differences in baseline vari-
ables when gender-specific interactions with weight and hemoglobin are omitted.
Introduction
Nearly 10 million people were receiving antiretroviral therapy (ART) in low and middle-
income countries by the end of 2012, an estimated 61% of patients who were eligible under the
2010 World Health Organization (WHO) guidelines [1]. Though ART scale-up is widely
viewed as highly successful, questions have been raised about gender equity in access to services
[2–5]. Women have been prioritized by funding agencies, international organizations, and
local governments, with a focus on the prevention of mother-to-child transmission of HIV [6].
These efforts have resulted in proportionally greater numbers of women receiving HIV testing
and ART [7].
Male gender is associated with late HIV testing and more advanced disease at ART initiation
[8–18], which is strongly associated with poorer outcomes [19]. Even after controlling for dif-
ferences in disease severity and other baseline characteristics, multiple studies have found that
males have higher mortality after ART initiation [8, 10–13, 20–33]. Proposed reasons for this
mortality difference include inequality for males in health care systems in low and middle-
income countries, poorer treatment adherence, irregular clinic attendance due to work-related
responsibilities, a higher baseline mortality rate for males in the general population, potentially
biological differences, and other unmeasured confounders or uncharacterized mechanisms
that lead to poorer outcomes for males [2, 3, 5, 8, 12, 34–37].
In Haiti, we found differing results in two studies on predictors of mortality after ART initi-
ation. The earlier study included gender-specific weight quartiles, and did not find an associa-
tion between male gender and mortality (hemoglobin was not included in the analyses) [38].
The later study included weight and hemoglobin as continuous variables, and found that male
gender was associated with higher mortality [39]. We reviewed the literature, and found that
many other ART outcomes studies also included weight and hemoglobin without sex-specific
categories [8–12, 20–23, 30, 31, 33]. These analyses compare mortality among males vs. females
with the same weight and hemoglobin. Due to normal sex differences in these variables, this is
not a comparison of males and females of equivalent health status. We therefore repeated the
analyses for our later study, adding sex-specific categories for weight and hemoglobin.
Methods
Study Setting and Participants
The Haitian Group for the Study of Kaposi’s Sarcoma and Opportunistic Infections is a Haitian
non-governmental organization, and the oldest and largest provider of HIV services in the
Caribbean. GHESKIO has provided voluntary counseling and testing (VCT) for HIV since
1985. This study included all ART-naïve HIV-infected patients 13 years or older who were
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consecutively enrolled on ART from February 1, 2003 (when ART became widely available at
GHESKIO) to December 31, 2008. Patients were followed until December 31, 2009.
Data Collection and Statistical Analyses
Data were extracted from the GHESKIO electronic medical record and entered into a Micro-
soft Access database (Microsoft, Redmond, WA). Baseline weight, hemoglobin, and CD4 cell
count were defined as the measurement closest to the date of ART initiation, but not more
than six months before or two weeks afterwards. Death was ascertained by chart review, phone
calls to next of kin, and home visits. Patients were considered to be alive and in-care if they
were not known to be dead and had at least one visit within 6 months of the study endpoint.
All analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC). Patients who
were lost to care or transferred to other clinics were censored at their last visit.
Differences between males and females in age, education, income, TB status at ART initia-
tion, initial ART regimen (drug class), and baseline weight, hemoglobin and CD4 cell count
were compared using the Chi-square test for binary variables and Wilcoxon rank-sum test for
continuous variables. Cox proportional hazards models were used to assess the relationship
between baseline demographic and clinical variables and time to death after ART initiation.
Gender, income, education, initial ART regimen, and active TB co-infection at ART initiation
were defined as binary variables; and hemoglobin, weight, age and CD4 cell count were defined
as continuous variables. In the multivariable models we included all variables significant at the
0.20 level in univariable analyses.
We included weight and hemoglobin in the analyses of all-cause mortality using five different
models. In Model 1, we included baseline weight and hemoglobin as control variables, without
specifying these variables differently for males and females; the interpretation of this model is
the risk of mortality for males vs. females who presented with the same baseline weight and
hemoglobin. In Model 2, we included weight and hemoglobin using differences from the sex-
specific median; the interpretation of this model is the risk of mortality for males vs. females
who have the same deviation from the sex-specific cohort medians for these variables. The goal
of Model 3 was to compare mortality for males vs. females with the same deviation from a
healthy sex-specific standard for weight and hemoglobin. Since there is no standard measure of
healthy weight without the inclusion of height, and height was not measured, we used deviation
from gender-specific median for weight. For hemoglobin, we used theWHO definition of ane-
mia as a binary variable (cut-off of 12 g/dL for women and 13 g/dL for men) [40]. In Model 4,
we used sex-specific quartiles for weight and hemoglobin; the interpretation of this model is the
risk of mortality for males vs. females who fall within the same sex-specific cohort quartiles for
these variables. In Model 5, we excluded any weight or hemoglobin-related variables but
included all other variables as in the other models. Our rationale for the inclusion of Model 5 is
for comparability with other studies that did not include these variables. We included an anon-
ymized dataset (see S1 Appendix) that includes all data needed to reproduce these results.
Ethics Statement
This study was approved by the ethics committees of GHESKIO, Weill Cornell Medical College,
and Brigham andWomen’s Hospital. It was not feasible to obtain informed consent for this ret-
rospective study, but patient information was anonymized and de-identified prior to analysis.
Results
The 4,717 ART-naïve HIV-infected patients age 13 years or older who were consecutively
enrolled on ART during the study period were included. Characteristics for males and females
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are summarized in Table 1. The cohort included 2,151 males (46%) and 2,566 females (54%).
Males were older (median age 40 vs. 36 years; p<0.0001), less likely to live onUS$365/year
(53% vs. 71%; p<0.0001), less likely to have no school or primary school only (43% vs. 56%;
p<0.0001), and more likely to have TB at ART initiation (6% vs. 4%; p<0.0001). At baseline,
males had higher median body weight (57 vs. 50 kilograms; p<0.0001), higher median hemo-
globin (11.0 vs. 10.0 g/dl; p<0.0001), and lower median CD4 counts (134 vs. 105 cells/mm3).
The median follow-up time was 828 days (interquartile range (IQR): 388 to 1,505 days) for
males and 825 days (IQR: 395 to 1,492 days) for females. Of the 4717 patients in the cohort,
293 males (14%) and 305 females (12%) died during the study period; 602 patients (13%) were
lost to follow-up, including 288 males (13%) and 314 females (12%). The LTFU rates were not
statistically significantly different between sexes (p = 0.2375).
Univariable and Multivariable Analyses without Sex-Specific Categories
for Weight and Hemoglobin
We conducted Cox proportional hazards regression with baseline weight and hemoglobin as
non-sex specific variables. In the univariable analysis, gender, age, income, weight, hemoglobin,
CD4 cell count, and TB status at ART initiation had p-values<0.20, and were included in the
multivariable analyses. Education and ART regimen were not associated with mortality
(p = 0.503 and 0.674, respectively) and were excluded from further analyses.
The sample size for the multivariable analysis was 3761 patients. Nine hundred fifty-six
patients were missing at least one of the independent variables. Male gender (adjusted hazard
ratio [aHR] 1.61; 95% CI: 1.30–2.00) and older age were associated with mortality (aHR 1.22
for every 10-year increase in age; 95% CI: 1.11–1.34). Higher baseline weight (aHR 0.63 for
every 10-kilogram increase in weight; 95% CI: 0.56–0.70), hemoglobin (aHR 0.87; 95% CI:
0.82–0.92), and CD4 cell count (aHR 0.87 for every 50 CD4 cells; 95% CI: 0.82–0.93) were asso-
ciated with improved survival (see Table 2, Model 1).
Multivariable Analyses Using Sex-Specific Categories for Weight and
Hemoglobin
We conducted three different additional analyses using sex-specific categories for weight and
hemoglobin, as described above (Models 2, 3, and 4). As illustrated in Tables 2 and 3, in each of
these three models, older age was associated with mortality. Higher baseline weight, hemoglo-
bin, and CD4 cell count were associated with improved survival. Male gender was not a predic-
tor of mortality.
We repeated the analyses with the exclusion of any baseline hemoglobin or weight control
variables, for comparison with studies that did not include these variables in the analyses (see
Table 4, Model 5). With the exclusion of these variables, male gender was not associated with
higher mortality. Older age and income$US 365 per year were associated with higher mor-
tality, and higher CD4 cell count was associated with improved survival.
Discussion
In Haiti, as in most other resource-poor settings, male gender is associated with advanced dis-
ease at ART initiation [8–18]. However, we found that after controlling for baseline differences,
the association between male gender and mortality on ART depended on whether or not sex-
specific categories were used for weight and hemoglobin. Without the use of sex-specific cate-
gories, we found that the adjusted hazard ratio of mortality for males was 1.61 (1.30–2.00).
Gender and Mortality on ART
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Male gender was not associated with mortality if sex-specific categories were used for weight
and hemoglobin, or these variables were excluded from the analysis.
Many studies from resource-poor settings have described higher rates of mortality for males
on ART [8–13, 17, 20–33, 41, 42]. However, these studies did not use sex-specific categories for
both weight and hemoglobin, and therefore indicate a higher mortality for males vs. females of
the same weight and hemoglobin. As the males in this comparison would generally have poorer
health status at equal baseline weight and hemoglobin levels, higher mortality would be
expected.
Table 1. Baseline Patient Characteristics by Gender.
Variable* Male (n = 2,151) Female (n = 2,566) P-value
Median Age (IQR)** 40 (33 to 46) 36 (33 to 43) <0.0001
No school or primary school only—no. (%) 931 (43) 1,435 (56) <0.0001
Income US$365/year—no. (%) 1,148 (53) 1,813 (71) <0.0001
Median weight—kilograms (IQR)** 57 (50–64) 50 (44–58) <0.0001
Median hemoglobin—g/dl (IQR)** 11.0 (9.6–12.2) 10.0 (8.9–11.0) <0.0001
Hemoglobin <8.0 (g/dl)–no. (%) 116 (5) 234 (9) <0.0001
Hemoglobin 8.0–10.9 (g/dl)–no. (%) 835 (39) 1,422 (55)
Hemoglobin 11.0–12.9 (g/dl)–no. (%) 694 (32) 585 (23)
Hemoglobin 13.0 287 (13) 46 (2)
Median CD4 cell count (IQR)** 105 (39–182) 134 (59–198) <0.0001
CD4 cell count <50 cells/mm3 561 (29) 513 (22) <0.0001
CD4 cell count 50–99 cells/mm3 372 (19) 404 (17)
CD4 cell count 100–199 cells/mm3 648 (33) 853 (36)
CD4 cell count  200 cells/mm3 370 (19) 573 (24)
TB at ART initiation—no. (%) 126 (6) 107 (4) 0.0077
ART regimen includes non-nucleoside reverse transcriptase inhibitor 2,044 (95) 2,431 (95) 0.6567
* Two variables had 5% of data missing. There were 219 (10%) missing hemoglobin results for males and 279 (11%) for females. There were 200 (9%)
missing CD4 count results for males and 223 (9%) for females.
**Median values and percentages are computed using the number of patients with non-missing values.
doi:10.1371/journal.pone.0142101.t001
Table 2. Cox Proportional Hazards Models of Mortality on ART using Different Methods of CategorizingWeight and Hemoglobin (Models 1, 2, and
3).
Variable Model 1: Weight and hemoglobin
as continuous variables
Model 2: Deviation from gender-
speciﬁc median for weight and
hemoglobin
Model 3: Deviation from gender-
speciﬁc median weight and
gender-speciﬁc WHO anemia
deﬁnition*
Adjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value
Male gender 1.61 (1.30–2.00) <0.0001 1.05 (0.85–1.29) 0.6437 1.04 (0.84–1.27) 0.7444
Age (unit = 10 years) 1.22 (1.11–1.34) <0.0001 1.22 (1.11–1.34) <0.0001 1.22 (1.11–1.34) <0.0001
Income $US365 per year 1.22 (0.97–1.54) 0.0884 1.22 (0.97–1.54) 0.0884 1.22 (0.97–1.54) 0.0884
Weight (unit = 10 kilograms) 0.63 (0.56–0.70) <0.0001 0.63 (0.56–0.70) <0.0001 0.63 (0.56–0.70) <0.0001
Hemoglobin (g/dl) 0.87 (0.82–0.92) <0.0001 0.87 (0.82–0.92) <0.0001 0.87 (0.82–0.92) <0.0001
CD4 cell count (unit = 50 cells) 0.87 (0.82–0.93 <0.0001 0.87 (0.82–0.93) <0.0001 0.87 (0.82–0.93) <0.0001
TB at ART initiation 1.39 (0.97–1.98) 0.0711 1.39 (0.97–1.99) 0.0711 1.39 (0.97–1.99) 0.0711
*Difference from gender-speciﬁc median for weight, and World Health Organization deﬁnition of anemia (12.0 g/dl for women and 13.0 g/dl for men)
doi:10.1371/journal.pone.0142101.t002
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Six of these studies from China, South Africa, and Tanzania included body weight in the
analyses without sex-specific categories [8, 10, 11, 22, 29, 33]. Though BMI is a superior predic-
tor of nutritional status as it includes height, it is not always available, and weight is used as a
proxy. All six of these studies found that male gender was associated with higher mortality.
Studies from Cambodia, Thailand, Burkina Faso, Cameroon, Cote d’Ivoire, Malawi, Nigeria
and Tanzania used body mass index, and none of these used sex-specific categories [9, 12, 20,
21, 23, 27, 28, 30, 31]. BMI is commonly used as a predictor of disease in high BMI ranges with-
out sex-specific categories. However, there is limited evidence linking low BMI ranges to dis-
ease outcomes in the developing country context, particularly when sex-specific categories are
not used [43–45]. In addition, BMI poorly discriminates between body composition pheno-
types, i.e. bone mass, fat mass and lean muscle mass [43, 46], and significant sex differences
exist in body composition phenotypes [43, 47, 48]. Thus, the same BMI value may have differ-
ent implications for the health and nutritional status of HIV-infected men and women.
Most studies from resource-poor settings that included hemoglobin did not include sex-spe-
cific categories [9, 11, 12, 20–23, 30, 31]. However, criteria for anemia are sex-specific. WHO
defines anemia as a hemoglobin level below 12 g/dL in females and below 13 g/dL in males
[40], and multiple studies evaluating outcomes in other diseases have used sex-specific catego-
ries for hemoglobin [49–53]. Most studies that did not use sex-specific hemoglobin categories
found an association between male gender and mortality [11, 12, 20–23, 30, 31]. One study
from Cambodia did not use sex-specific hemoglobin categories and found no association
Table 3. Cox Proportional Hazards Model of Mortality on ART Using Gender-Specific Quartiles for
Hemoglobin andWeight (Model 4).
Variable Model 4: Adjusted HR (95% CI) p-value
Male gender 1.12 (0.91–1.38) 0.2813
Age (unit = 10 years) 1.18 (1.08–1.30) <0.0001
Income $US365/year 1.30 (1.03–1.63) 0.0269
Weight—reference group bottom quartile
— Quartile 2 for gender 0.49 (0.37–0.64) <0.0001
— Quartile 3 for gender 0.41 (0.31–0.54) <0.0001
— Quartile 4 for gender 0.39 (0.28–0.54) <0.0001
Hemoglobin—reference group bottom quartile
— Quartile 2 for gender 0.58 (0.44–0.75) <0.0001
— Quartile 3 for gender 0.66 (0.50–0.87) 0.0029
— Quartile 4 for gender 0.47 (0.34–0.66) <0.0001
CD4 cell count (unit = 50 cells) 0.87 (0.82–0.92) <0.0001
TB at ART initiation 1.36 (0.95–1.95) 0.0910
doi:10.1371/journal.pone.0142101.t003
Table 4. Cox Proportional Hazards Models of Mortality on ART with the Exclusion of Weight and
Hemoglobin (Model 5).
Variable Model 5: No interaction
Adjusted HR (95% CI) p-value
Male gender 1.15 (0.93–1.41) 0.2003
Age (unit = 10 years) 1.16 (1.05–1.28) 0.0037
Income $US365 per year 1.53 (1.22–1.92) 0.0002
CD4 cell count (unit = 50 cells) 0.83 (0.78–0.88) <0.0001
TB at ART initiation 1.61 (1.13–3.00) 0.0886
doi:10.1371/journal.pone.0142101.t004
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between gender and mortality, but it included patients who were severely immunocompro-
mised (median CD4 cell count of 20 cells/mm3), making comparisons with other cohorts diffi-
cult [9]. One South African study included sex-specific categories for hemoglobin, and found
an association between male gender and mortality [8]. However, this study included weight as
a continuous variable, without sex-specific categories. The authors also compared the gender
differential in mortality among patients on ART to the background gender differential in mor-
tality in the South African population. They found that the gender mortality ratio among
patients on ART appeared to be smaller than the age-standardized HIV-negative mortality
ratio for men vs. women in South Africa, suggesting that higher background mortality rates
among males contributed to the association with mortality on ART. Therefore, the finding of
the association between male gender and mortality on ART could be misinterpreted.
Several studies from India, Ethiopia, Lesotho, Malawi, South Africa, and Uganda did not
include either weight or hemoglobin in the analyses [13, 17, 24–26, 32, 41, 42]. These studies
generally involved retrospective cohorts, and data for these variables had not been collected.
Hemoglobin and weight provide two additional metrics to proxy the underlying baseline health
status of patients, when they are available. Models that exclude hemoglobin and weight should
result in a weaker relationship between gender and mortality than models that include these
variables without attention to sex-specific differences in healthy values. However, because
these studies do not explicitly control for sex-specific differences in healthy weight and hemo-
globin levels, they are still likely to overstate male mortality. Some studies that had not included
these variables found an association between male gender and mortality on ART [13, 24–26,
32] while others did not [17, 41, 42].
Though our study found that male gender was not associated with higher mortality after
controlling for baseline characteristics that proxy for disease severity with attention to sex-spe-
cific differences in healthy weight and hemoglobin, this does not diminish concern about
equity in access to care for males [2–5, 13, 27, 28]. In our analysis as in others, males present
later for HIV testing, and start ART with more advanced disease; such delays in ART initiation
are associated with higher morbidity and poorer long-term survival [19]. Innovative outreach
efforts for earlier HIV testing and timely ART initiation for males remain critical to maximize
HIV treatment outcomes, particularly since our analysis shows that, controlling for baseline
characteristics that proxy for disease severity, there is no evidence of lower survival for males
relative to females after ART initiation.
Our study was limited by the use of retrospective data from a single country, and by our
lack of BMI data. It was also limited by the lack of information about mortality in patients who
were LTFU. We did not correct mortality for LTFU in our analyses. Our rate of LTFU (13%
with median follow-up time of 27 months) is lower than in many studies from resource-poor
settings [54, 55], and was similar in males and females. We wanted to compare our findings to
other published studies evaluating the sex differences in ART outcomes. These studies either
did not correct mortality for LTFU [10, 11, 20, 22, 27, 28, 30], conducted separate analyses to
identify predictors of mortality and LTFU [12, 17, 23–25, 31, 32, 42], or used weighted data or
competing risk models (either in the base case analysis or in sensitivity analyses) to correct
mortality estimates for those who were LTFU but had died [8, 9, 13, 21, 26, 29, 33, 41].
In comparing our study with others from resource-poor settings that evaluated the associa-
tion between gender and mortality on ART, it is important to also consider that normal weight
and hemoglobin values vary by age and ethnicity. All patients in our cohort were Haitian, of
African descent. The median age in our study was 38 years, and we included patients of at least
13 years of age. The median age in other studies ranged from 32 to 39 years [8–13, 17, 20–33,
41, 42], and many included adolescents as well as adult patients [8, 12, 13, 20, 21, 24–28, 32,
33].
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The association between gender and ART outcomes is complex, and the reasons for gender
differences vary by settings. However, our finding that the association between gender and
mortality is no longer observed once sex-specific baseline characteristics are included has rele-
vance for other countries and other diseases.
In summary, we found that males do not have higher mortality after ART initiation, as long
as sex-specific categories for weight and hemoglobin are included to allow a comparison of
gender-specific survival given similar morbidity levels at baseline. If sex-specific categories are
not used, then the hazard ratio must be interpreted as a comparison of males and females with
the same weight and hemoglobin but not the same baseline morbidity levels.
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